Skip to content

Arvinas ARVN Operating Income

Operating Income at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-$92.5M-47.1%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$84.15M-13.1%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
-$50.03M-214%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
-$19.46M-6.8%
Nuvectis Pharma, Inc. logo
Nuvectis Pharma, Inc.NVCT
-$6.26M-12.4%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-$46.11M+30.9%

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's operating income?
Arvinas (ARVN) reported operating income of -$63.8M in Q1 2026.
How has Arvinas's operating income changed year-over-year?
Arvinas's operating income decreased by 189.4% year-over-year, from $71.4M to -$63.8M.
What is the long-term trend for Arvinas's operating income?
Over 4 years (2021 to 2025), Arvinas's operating income has grown at a -10.9% compound annual growth rate (CAGR), from -$188.4M to -$118.5M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.